Jiangsu Yuyue Medical Equipment & Supply (002223) Q4 2025 earnings summary

Executive summary

• Achieved revenue of ¥7.96 billion in 2025, up 5.14% year-over-year, with net profit attributable to shareholders of ¥1.48 billion, down 17.94% year-over-year.

• Gross margin improved to 50.60%, up 0.46 percentage points year-over-year.

• Cash flow from operations was ¥1.50 billion, a decrease of 17.25% year-over-year.

• Significant growth in blood glucose management and POCT (+24.34%) and emergency solutions (+48.69%).

• International sales rose 29.86% year-over-year, with notable breakthroughs in Europe and the Americas.

Financial highlights

• Revenue: ¥7.96 billion (+5.14% YoY); Net profit: ¥1.48 billion (-17.94% YoY); Operating profit: ¥1.70 billion (-11.97% YoY).

• R&D expenses: ¥570 million, 7.17% of revenue.

• Total assets: ¥16.08 billion (+2.80% YoY); Net assets: ¥13.24 billion (+5.63% YoY).

• Basic and diluted EPS: ¥1.48 (-18.23% YoY).

• Cash dividend payout ratio: 67.65% of net profit.

Outlook and guidance

• Focus on "globalization, digitalization, and wearables" as core strategies.

• Plans to strengthen R&D, accelerate product innovation, and expand international presence.

• Continued investment in high-potential segments such as emergency and ophthalmology.

• Emphasis on cost control, supply chain optimization, and digital transformation.